ArticleTranslational cancer research2026
IGF2BP3 promotes immune evasion and predicts poor prognosis in head and neck squamous cell carcinoma.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Head and neck squamous cell carcinoma (HNSCC) is a common malignancy with high mortality and limited prognostic biomarkers. The RNA-binding protein insulin-like growth factor 2 messenger RNA-binding protein 3 (IGF2BP3) recognizes N6-methyladenosine (m6A) and promotes tumor progression in multiple cancers, but its prognostic value and immunological role in HNSCC remain unclear. This study aims to explore the role of IGF2BP3 in the pathogenesis of HNSCC, investigate its potential as a reliable diagnostic and prognostic biomarker, and assess its applicability as a novel immunotherapeutic target, with the goal of improving clinical outcomes for patients with HNSCC. Methods: IGF2BP3 expression and its association with clinicopathological features and survival were analyzed using The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx) datasets. Receiver operating characteristic (ROC) curves and multivariate Cox regression were used to evaluate its diagnostic and prognostic value. Co-expressed genes were identified via cBioPortal, followed by Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and protein-protein interaction (PPI) analyses. Immune cell infiltration was estimated using single-sample gene set enrichment analysis (ssGSEA). The functional role of IGF2BP3 was validated in SCC-25 cells using small interfering RNA (siRNA) knockdown, Cell Counting Kit-8 (CCK-8) proliferation assays, wound-healing assays, and Transwell migration/invasion assays. Results: IGF2BP3 messenger RNA (mRNA) and protein were significantly upregulated in HNSCC tissues compared with normal controls (P<0.001). ROC analysis yielded an area under the curve (AUC) of 0.809 [95% confidence interval (CI): 0.753-0.866], indicating good diagnostic performance. High IGF2BP3 expression was associated with advanced clinical stage and independently predicted worse overall survival in multivariate Cox analysis. Enrichment analyses suggested that IGF2BP3-related genes were involved in metabolic reprogramming and RNA-binding protein networks. IGF2BP3 expression correlated positively with Th2 cells and negatively with cytotoxic T and natural killer (NK) cells, indicating an immunosuppressive tumor microenvironment. Functionally, IGF2BP3 knockdown significantly inhibited SCC-25 cell proliferation, migration, and invasion Conclusions: IGF2BP3 is overexpressed in HNSCC and is associated with advanced stage, unfavorable prognosis, and an immunosuppressive immune landscape. IGF2BP3 represents a promising diagnostic and prognostic biomarker and may constitute a potential therapeutic target in HNSCC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.